REGN monthly performance report
Check REGN's monthly returns, drawdown, and seasonality trends — updated every month.
REGN monthly report
—
Key takeaways
- Regeneron Pharmaceuticals (REGN) closed September 2026 at $774.61, down 3.06% for the month and +34.70% over the trailing 12 months.
- Year-to-date, REGN is +0.35%, underperforming the S&P 500 which has returned +10.58% YTD.
- The stock is trading +5.45% versus its 200-day moving average ($734.61), a bullish technical signal.
- Over the past three years, REGN has underperformed the S&P 500 by −76.00%, with a relative strength index reading of 55.3.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 19 negative months.
Regeneron Pharmaceuticals ended September 2026 at $774.61, posting a monthly return of −3.06%. The S&P 500 returned −1.69% over the same window, leaving relative performance at −1.37%.
The current quarter stands at +24.23% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +5.45% versus the 200-day moving average ($734.61).
Year-to-date, REGN is +0.35% against SPY +10.58%, a gap of −10.22%. The stock is currently −9.35% below its 52-week high, with maximum 3-year drawdown at −59.80%.
| Period | REGN | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +0.06% | −0.44% | +0.51% |
| 1 Week | −4.09% | −1.10% | −3.00% |
| 1 Month | −3.06% | −1.69% | −1.37% |
| 3 Months | +26.54% | −0.10% | +26.64% |
| 6 Months | −0.01% | +13.21% | −13.22% |
| YTD | +0.35% | +10.58% | −10.22% |
| 12 Months | +34.70% | +14.25% | +20.45% |
| 3 Years | −5.93% | +70.07% | −76.00% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jul 2026 | +22.31% |
| #2 | Nov 2025 | +19.70% |
| #3 | Oct 2025 | +15.92% |
| #4 | Aug 2023 | +11.40% |
| #5 | May 2024 | +10.05% |
| Rank | Month | Return |
|---|---|---|
| #1 | Oct 2024 | −20.27% |
| #2 | May 2025 | −18.12% |
| #3 | May 2026 | −13.05% |
| #4 | Sep 2024 | −11.26% |
| #5 | Nov 2024 | −10.50% |
| Quarter | Return |
|---|---|
| Q2 2025 | −17.22% |
| Q3 2025 | +7.10% |
| Q4 2025 | +37.28% |
| Q1 2026 | +0.10% |
| Q2 2026 | −19.30% |
| Q3 2026 (QTD) | +24.23% |
| Year | Return |
|---|---|
| 2023 | +21.73% |
| 2024 | −18.90% |
| 2025 | +8.36% |
| 2026 | +0.35% |
| Metric | Value |
|---|---|
| 52-Week High | $854.49 (2026-09-02) |
| 52-Week Low | $541.00 (2025-10-13) |
| Current Price | $774.61 |
| 200-Day Moving Average | $734.61 |
| Price vs 200DMA | +5.45% |
| 3-Year Maximum Drawdown | −59.80% (2025-06-05) |
| Current Drawdown from 52W High | −9.35% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 55.3 |
| 3-Year Excess Return vs S&P 500 | −76.00% |
| RS Peak | 115.6 (Aug 2024) |
| RS Trough | 42.6 (Jun 2026) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was REGN's return for this report period?
REGN returned −3.06% in the latest monthly window ending 2026-09-16.
Has REGN outperformed SPY year to date?
YTD REGN: +0.35% vs SPY: +10.58%.
What is REGN's 12-month return?
+34.70% over the trailing 12 months.
Is REGN above or below its 200-day moving average?
Price is +5.45% versus 200DMA ($734.61).
What is the maximum drawdown in the 3-year window?
−59.80% on 2025-06-05.